Remedy Meds agreement to acquire Thirty Madison for $500 million marks a significant moment in the evolution of direct-to-consumer digital health and pharmacy platforms in women’s health. This deal brings together Remedy Meds’ rapid growth in telehealth-enabled pharmacy services with Thirty Madison’s established suite of specialty care brands, spanning women’s health, men’s health, and chronic condition care. The combination is poised to create one of the largest consumer-focused virtual care platforms in the U.S.
Remedy Meds launched in 2024 with a focus on telemedicine for weight-management therapies and a vertically integrated pharmacy model. It rapidly scaled its business, projecting more than $450 million in revenue for 2025 and profitability. Thirty Madison has roots going back to 2017 and is a portfolio of consumer health brands such as Nurx (women’s health and reproductive care), Keeps (men’s hair loss), and Cove (migraine treatment). Thirty Madison brings valuable brand recognition, clinical infrastructure, and patient relationships to the combined entity.
For women’s health innovators in particular, the transaction highlights the exit opportunities in a maturing digital health market. Thirty Madison’s sale for more than half a billion dollars underscores that women’s health remains a valuable and investable category.
We’re already seeing a number of early-stage players scale in the digital pharmacy and consumer health space that are poised to exit following the success of Remedy Meds and Thirty Madison. Examples of emerging innovation:
Alloy (Amboy Street portfolio company; Series A) — Virtual menopause care platform and pharmacy
Hey Jane (Amboy Street portfolio company; Series A) — Digital reproductive and sexual healthcare platform including abortion care and virtual pharmacy
Evvy (Amboy Street portfolio company; Series A) — Women’s vaginal health testing and care platform
